A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Multiple Oral Doses (6 Days) of 100 mg Resmetirom in Subjects With Severe Renal Impairment and in Matched Healthy Control Subjects With Normal Renal Function

PHASE1CompletedINTERVENTIONAL
Enrollment

28

Participants

Timeline

Start Date

March 6, 2024

Primary Completion Date

September 16, 2024

Study Completion Date

December 31, 2024

Conditions
Renal Impairment
Interventions
DRUG

100 mg Resmetirom Tablet

Once daily oral dose for 6 days

Trial Locations (3)

32809

Madrigal Research Center, Orlando

33603

Madrigal Research Center, Tampa

60643

Madrigal Research Center, Chicago

Sponsors
All Listed Sponsors
lead

Madrigal Pharmaceuticals, Inc.

INDUSTRY